{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:45:11Z","timestamp":1790779511166,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"17","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Tianjin Education Commission social science major project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41433-025-03964-2","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:25:17Z","timestamp":1759314317000},"page":"3105-3112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Twice versus once daily application of 0.01% atropine for myopia control in children: a randomised controlled trial"],"prefix":"10.1038","volume":"39","author":[{"given":"Meinan","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9708-0355","authenticated-orcid":false,"given":"Ruihua","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"3964_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/519276a","volume":"519","author":"E Dolgin","year":"2015","unstructured":"Dolgin E. The myopia boom. Nature. 2015;519:276\u20138.","journal-title":"Nature"},{"key":"3964_CR2","doi-asserted-by":"publisher","first-page":"e639","DOI":"10.1111\/aos.14350","volume":"98","author":"JC Yam","year":"2020","unstructured":"Yam JC, Tang SM, Kam KW, Chen LJ, Yu M, Law AK, et al. High prevalence of myopia in children and their parents in Hong Kong Chinese Population: the Hong Kong Children Eye Study. Acta Ophthalmol. 2020;98:e639\u2013e648.","journal-title":"Acta Ophthalmol"},{"key":"3964_CR3","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, Jong M, Naidoo KS, Sankaridurg P, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmol. 2016;123:1036\u201342.","journal-title":"Ophthalmol"},{"key":"3964_CR4","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1038\/s41598-024-54325-0","volume":"14","author":"H Wang","year":"2024","unstructured":"Wang H, Xu Z, Chen D, Li H, Zhang J, Liu Q, et al. Prevalence and causes of blindness and distance visual impairment in Chinese adult population in 2022 during the COVID-19 pandemic: a cross-sectional study. Sci Rep. 2024;14:3890.","journal-title":"Sci Rep"},{"key":"3964_CR5","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.jtho.2022.07.149","volume":"17","author":"SHI Ou","year":"2022","unstructured":"Ou SHI, Nishio M, Yoshida T, Kumagai T, Ahn MJ, Mok T, et al. MA13.03 integrated efficacy and safety of Brigatinib following Alectinib treatment in the ALTA-2 and J-ALTA studies. J Thorac Oncol. 2022;17:S89.","journal-title":"J Thorac Oncol"},{"key":"3964_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Investig Ophthalmol Vis Sci. 2020;61:49.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3964_CR7","volume":"2023","author":"JG Lawrenson","year":"2023","unstructured":"Lawrenson JG, Shah R, Huntjens B, Downie LE, Virgili G, Dhakal R, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2023;2023:CD014758.","journal-title":"Cochrane Database Syst Rev"},{"key":"3964_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.22336\/rjo.2020.40","volume":"64","author":"S Tone","year":"2020","unstructured":"Tone S, Niagu IA, Bogdanici ST, Bogdanici CM. Update in pediatric myopia treatment strategies. Rom J Ophthalmol. 2020;64:233\u20138.","journal-title":"Rom J Ophthalmol"},{"key":"3964_CR9","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2015.10803","volume":"314","author":"M He","year":"2015","unstructured":"He M, Xiang F, Zeng Y, Mai J, Chen Q, Zhang J, et al. Effect of time spent outdoors at school on the development of myopia among children in China: a randomized clinical trial. JAMA. 2015;314:1142\u20138.","journal-title":"JAMA"},{"key":"3964_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/opo.12332","volume":"37","author":"SM Li","year":"2017","unstructured":"Li SM, Kang MT, Wu SS, Meng B, Sun YY, Wei SF, et al. Studies using concentric ring bifocal and peripheral add multifocal contact lenses to slow myopia progression in school-aged children: a meta-analysis. Ophthalmic Physiol Opt. 2017;37:51\u201359.","journal-title":"Ophthalmic Physiol Opt"},{"key":"3964_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, Fogt JS, Blumenfeld LC, Fong TM, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial. JAMA Ophthalmol. 2023;141:990\u20139.","journal-title":"JAMA Ophthalmol"},{"key":"3964_CR12","first-page":"157","volume":"7","author":"R Kaiti","year":"2022","unstructured":"Kaiti R, Shyangbo R, Sharma IP. Role of Atropine in the control of myopia progression- a review. Beyoglu Eye J. 2022;7:157\u201366.","journal-title":"Beyoglu Eye J"},{"key":"3964_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1167\/iovs.62.5.6","volume":"62","author":"JB Jonas","year":"2021","unstructured":"Jonas JB, Ang M, Cho P, Guggenheim JA, He MG, Jong M, et al. IMI prevention of myopia and its progression. Investig Ophthalmol Vis Sci. 2021;62:6.","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"3964_CR14","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua W-H, Cheung Y-B, Wong W-L, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmol. 2012;119:347\u201354.","journal-title":"Ophthalmol"},{"key":"3964_CR15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu Q-S, Tan D. Five-year clinical trial on atropine for the treatment of myopia 2. Ophthalmol. 2016;123:391\u20139.","journal-title":"Ophthalmol"},{"key":"3964_CR16","doi-asserted-by":"publisher","first-page":"461","DOI":"10.4103\/ijo.IJO_1457_18","volume":"67","author":"SS Kesarwani","year":"2019","unstructured":"Kesarwani SS, Mumbai Group of Paediatric O & Strabismologists. Consensus statement and guidelines for use of dilute atropine sulphate in myopia control. Indian J Ophthalmol. 2019;67:461\u20133.","journal-title":"Indian J Ophthalmol"},{"key":"3964_CR17","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","volume":"141","author":"MX Repka","year":"2023","unstructured":"Repka MX, Weise KK, Chandler DL, Wu R, Melia BM, Manny RE, et al. Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial. JAMA Ophthalmol. 2023;141:756\u201365.","journal-title":"JAMA Ophthalmol"},{"key":"3964_CR18","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/ceo.14148","volume":"50","author":"SSY Lee","year":"2022","unstructured":"Lee SSY, Lingham G, Blaszkowska M, Sanfilippo PG, Koay A, Franchina M, et al. Low-concentration atropine eyedrops for myopia control in a multi-racial cohort of Australian children: a randomised clinical trial. Clin Exp Ophthalmol. 2022;50:1001\u201312.","journal-title":"Clin Exp Ophthalmol"},{"key":"3964_CR19","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1111\/aos.15761","volume":"102","author":"J Loughman","year":"2024","unstructured":"Loughman J, Kobia-Acquah E, Lingham G, Butler J, Loskutova E, Mackey DA, et al. Myopia outcome study of atropine in children: two-year result of daily 0.01% atropine in a European population. Acta Ophthalmol. 2024;102:e245\u2013e256.","journal-title":"Acta Ophthalmol"},{"key":"3964_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, Tang SM, Yip BHK, Kam KW, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study. Ophthalmol. 2020;127:910\u20139.","journal-title":"Ophthalmol"},{"key":"3964_CR21","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.ajo.2015.01.029","volume":"159","author":"K-L Loh","year":"2015","unstructured":"Loh K-L, Lu Q, Tan D, Chia A. Risk factors for progressive myopia in the atropine therapy for myopia study. Am J Ophthalmol. 2015;159:945\u20139.","journal-title":"Am J Ophthalmol"},{"key":"3964_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","volume":"119","author":"A Chia","year":"2012","unstructured":"Chia A, Chua WH, Cheung YB, Wong WL, Lingham A, Fong A, et al. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Ophthalmology. 2012;119:347\u201354.","journal-title":"Ophthalmology"},{"key":"3964_CR23","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1038\/s41433-023-02534-8","volume":"37","author":"G Zhang","year":"2023","unstructured":"Zhang G, Jiang J, Qu C. Myopia prevention and control in children: a systematic review and network meta-analysis. Eye. 2023;37:3461\u20139.","journal-title":"Eye"},{"key":"3964_CR24","doi-asserted-by":"publisher","first-page":"1125000","DOI":"10.3389\/fpubh.2023.1125000","volume":"11","author":"C Lanca","year":"2023","unstructured":"Lanca C, Pang CP, Grzybowski A. Effectiveness of myopia control interventions: a systematic review of 12 randomized control trials published between 2019 and 2021. Front Public Health. 2023;11:1125000.","journal-title":"Front Public Health"},{"key":"3964_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ajo.2013.09.020","volume":"157","author":"A Chia","year":"2014","unstructured":"Chia A, Chua W-H, Wen L, Fong A, Goon YY, Tan D. Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%. Am J Ophthalmol. 2014;157:451\u20137.e451.","journal-title":"Am J Ophthalmol"},{"key":"3964_CR26","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, Law AKP, Chan JJ, Wong E, et al. Low-concentration atropine for myopia progression (LAMP) study. Ophthalmol. 2019;126:113\u201324.","journal-title":"Ophthalmol"},{"key":"3964_CR27","doi-asserted-by":"crossref","unstructured":"Moriche-Carretero M, Revilla-Amores R, Guti\u00e9rrez-Blanco A, Moreno-Morillo FJ, Martinez-Perez C, S\u00e1nchez-Tena M\u00c1, et al. Five-year results of atropine 0.01% efficacy in the myopia control in a European population. Br J Ophthalmol. 2024;108:715-719.","DOI":"10.1136\/bjo-2022-322808"},{"key":"3964_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.exer.2013.04.018","volume":"114","author":"AN French","year":"2013","unstructured":"French AN, Ashby RS, Morgan IG, Rose KA. Time outdoors and the prevention of myopia. Exp Eye Res. 2013;114:58\u201368.","journal-title":"Exp Eye Res"},{"key":"3964_CR29","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.2147\/OPTH.S245192","volume":"14","author":"LS Eppenberger","year":"2020","unstructured":"Eppenberger LS, Sturm V. The role of time exposed to outdoor light for myopia prevalence and progression: a literature review. Clin Ophthalmol. 2020;14:1875\u201390.","journal-title":"Clin Ophthalmol"},{"key":"3964_CR30","doi-asserted-by":"publisher","first-page":"e256","DOI":"10.1111\/aos.13904","volume":"97","author":"S Ulaganathan","year":"2019","unstructured":"Ulaganathan S, Read SA, Collins MJ, Vincent SJ. Influence of seasons upon personal light exposure and longitudinal axial length changes in young adults. Acta Ophthalmol. 2019;97:e256\u2013e265.","journal-title":"Acta Ophthalmol"},{"key":"3964_CR31","first-page":"161","volume":"21","author":"J Jiang","year":"2019","unstructured":"Jiang J. Expert consensus on myopia management white paper (2019). Chinese J Optom Ophthalmol Vis Sci. 2019;21:161\u20135.","journal-title":"Chinese J Optom Ophthalmol Vis Sci"},{"key":"3964_CR32","unstructured":"EWoEcotaoalimpacm. Expert consensus on the application of axial length in myopia prevention and control management (2023). Chin J Exp Ophthalmol. 2024;42:1\u201311."},{"key":"3964_CR33","doi-asserted-by":"publisher","first-page":"M106","DOI":"10.1167\/iovs.18-25958","volume":"60","author":"CF Wildsoet","year":"2019","unstructured":"Wildsoet CF, Chia A, Cho P, Guggenheim JA, Polling JR, Read S, et al. IMI \u2013 Interventions for controlling myopia onset and progression report. Invest Ophthalmol Vis Sci. 2019;60:M106\u201331.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"3964_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2147\/TCRM.S265945","volume":"16","author":"J Cheng","year":"2020","unstructured":"Cheng J, Yang Y, Kong X, Zeng L, Chen Z, Xu J, et al. The effect of 0.01% atropine eye drops on the ocular surface in children for the control of myopia\u2014the primary results from a six-month prospective study. Ther Clin Risk Manag. 2020;16:735\u201340.","journal-title":"Ther Clin Risk Manag"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03964-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03964-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03964-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:04:46Z","timestamp":1763424286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-03964-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":34,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3964"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-03964-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"assertion":[{"value":"14 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}